PsyLabs, a strategic investment of Psyence BioMed, will attend ICPR 2026 as a Gold Sponsor. The team will engage with researchers, clinicians, regulators, and industry leaders to discuss psychedelic therapeutics, pharmaceutical-grade manufacturing, and the future of the sector.
Psyence BioMed CEO Jody Aufrichtig was featured in POLITICO’s Prescription Pulse discussing ibogaine, manufacturing, regulation and ethical sourcing.
Published on States of Mind, a leading digital publication dedicated to evidence-based mental health, neuroscience, and emerging therapies, this article is written by Stephanie Price and clinically reviewed by Christian Snuffer, a Clinical Mental Health Counselor.
Psyence BioMed’s 2025 results reflect a year of meaningful clinical and operational progress. We dosed our first patients in the Australian Phase IIb trial, expanded recruitment capacity, and strengthened our partnership with Southern Star Research. Our investment in PsyLabs secured sustainable, GMP compliant access to psilocybin and ibogaine, supporting our leadership in nature derived psychedelic therapeutics. With renewed Nasdaq compliance, strong cash reserves, and growing regulatory momentum, we enter 2026 positioned to lead in psychedelic medicine and longevity science.
Human longevity is shifting from a scientific pursuit to a global movement that challenges how we think about aging. In this opinion piece, Jody Aufrichtig, CEO of Psyence BioMed, explores why nature derived psychedelic compounds, especially psilocybin, may hold the key to one of the most significant breakthroughs in modern biology. Instead of treating aging as an unavoidable decline, he argues that we are entering a period where its underlying processes can be understood and influenced. Early research suggests that psilocybin may affect inflammation, oxidative stress, neuroplasticity, and cellular resilience, which are central to biological aging. Psyence BioMed has launched the first publicly listed psilocybin longevity research initiative to examine these effects with scientific rigor. The goal is not only to extend life, but to expand human potential through approaches that integrate psychological wellbeing, cellular health, and brain function as one interconnected system.
Psyence BioMed will host an exclusive investor and shareholder webinar on September 16, 2025, at 12:00 PM EST, featuring members of its Scientific Advisory Board. The session will highlight the Company’s ongoing clinical development programs and share insights into future strategic initiatives, with expert contributions from Dan Stein, Seth Feuerstein, Albert Garcia-Romeu, and Clive Ward-Able.
Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that it will present at the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8–10, 2025.
Psyence BioMed, in collaboration with Southern Star Research, has been featured on Channel 9 News Australia for our role in advancing clinical research into the use of psilocybin-assisted psychotherapy for cancer patients experiencing emotional distress.
Psyence Biomed is pleased to announce that its strategic partner, PsyLabs – a leader in the production of purified psychedelic compounds – has successfully produced a GMP-aligned Ibogaine Total Alkaloid extract.
Discover the future of mental health care through the eyes of Tony Budden, CEO of PsyLabs, in his thought-provoking feature in Insights Care Magazine. As a pioneer in the development of nature-derived psychedelic compounds like psilocybin and ibogaine, PsyLabs—working in close partnership with Psyence Biomed—is advancing groundbreaking solutions for substance use disorders and other mental health challenges.
